EDIT · Editas Medicine, Inc.
$2.82
+0.01 (+0.36%)
At close · Aug 14
Market Cap
$433.10M
Shares
153.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.82
Open$2.81
Day$2.72–2.85
52W close$1.67–4.15
Avg vol 30d1.8M
Short int23.5M · 15.3% float · 18.2d
Short vol56%
Last earningsMay 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
−2%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+49%
trailing
YTD return
+38%
this year
Relative strength
+35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.28% of float · ▲ +5.7% MoM · 18.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
214 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+133%
Y/Y
EPS growth
+38%
Y/Y
Free cash flow
$-165.8M
Balance sheet
$88.0M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.28% of float · ▲ +5.7% MoM · 18.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
214 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 46%
Range high $4
vs 200-day avg +9%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDIT
this stock
Editas Medicine, Inc.
|
$433.10M | +37.6% | +132.6% | — | 15.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDIT | -2.1% | -5.4% | +49.2% | +9.3% | +37.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.5% | -9.8% | +35.4% | +5.4% | +23.7% |
Key facts
CIK
1650664
CUSIP
28106W103
13F (30d)
226 filings
201 filers
Visit website
Investor relations